All In Biotech

Drug Trial Radar · NCT00134563

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses

Last checked: Nov 20, 2026Latest source record: Jan 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,088 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,088

Actual

Start

Sep 2004

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS). Secondary objectives were: * to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burden of disease as measured by Magnetic Resonance Imaging \[MRI\] and patient-reported fatigue; * to evaluate the safety and tolerability of teriflunomide.

Conditions

  • Multiple Sclerosis

Interventions

  • TeriflunomideDrug

    Film-coated tablet Oral administration

  • Placebo (for teriflunomide)Drug

    Film-coated tablet Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate [ARR]: Poisson Regression EstimatesTime frame: 108 weeks

Locations

21 sites in 21 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Bridgewater, New Jersey

  • Sanofi-Aventis Austria

    Vienna, Austria

  • sanofi-aventis, Canada

    Laval, Canada

  • Sanofi-Aventis

    Santiago, Chile

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • sanofi-aventis Denmark

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Tallinn, Estonia

  • sanofi-aventis Finland

    Helsinki, Finland

  • sanofi-aventis France

    Paris, France

  • Sanofi-Aventis Deutschland GmbH

    Berlin, Germany

  • Sanofi-Aventis

    Milan, Italy

  • Sanofi-Aventis

    Gouda, Netherlands

  • Sanofi-Aventis

    Lysaker, Norway

  • sanofi-aventis Poland

    Warsaw, Poland

  • Sanofi-Aventis

    Porto Salvo, Portugal

  • Sanofi-Aventis

    Moscow, Russia

  • Sanofi-Aventis

    Bromma, Sweden

  • Sanofi-Aventis Switzerland

    Geneva, Switzerland

  • sanofi-aventis Turkey

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis Administrative Office

    Kiev, Ukraine

  • sanofi-aventis UK

    Guildford, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.